Rosacea Market Report 2026

The rosacea market size has grown strongly in recent years. It will grow from $2.14 billion in 2025 to $2.33 billion in 2026 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to increasing prevalence of chronic inflammatory skin conditions, rising dermatology consultations, wider availability of topical antibiotics and alpha agonists, growing awareness of rosacea symptoms, improved access to dermatology care.

The rosacea market size is expected to see strong growth in the next few years. It will grow to $3.34 billion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to increasing demand for personalized treatment regimens, rising research into inflammatory skin disorders, growing adoption of novel drug classes, expansion of teledermatology services, increasing focus on quality-of-life improvement. Major trends in the forecast period include increasing adoption of targeted topical therapies, growing focus on long-term disease management solutions, rising demand for combination drug therapies, expansion of personalized dermatology treatments, enhanced emphasis on early diagnosis and symptom control.

The rising prevalence of skin diseases is expected to drive the growth of the rosacea market in the coming years. Skin diseases are medical conditions that affect the appearance, structure, and function of the skin, and can also involve the hair, nails, and related tissues. Rosacea, a type of inflammatory skin condition, can be triggered by various factors, including fungal infections such as Candida overgrowth. Additionally, rosacea is associated with a statistically significant increased risk of certain cancers, including hepatic cancer, non-melanoma skin cancer, and breast cancer. For example, in February 2023, Cancer Research UK, a UK-based cancer research organization, reported that the annual number of new melanoma cases in the UK is expected to rise from approximately 20,800 cases in 2023-2025 to around 26,500 cases in 2038-2040. This represents a projected 9% increase in melanoma incidence rates, reaching 33 cases per 100,000 people annually by 2038-2040. Therefore, the growing prevalence of skin diseases is supporting the growth of the rosacea market.

Key companies in the rosacea market are focusing on technological innovations, such as Expert Pulsed Light (XPL) systems, to meet the rising demand for non-invasive, highly effective, and versatile treatments driven by patient preference for minimal downtime and compatibility with diverse skin types. XPL technology represents an advanced evolution of pulsed light treatments, incorporating sophisticated pulse design, multiple expert filters, and sub-pulsing techniques to provide precise control of energy delivery and treatment protocols compared with traditional intense pulsed light (IPL) devices, which often offer less customizable outcomes. For instance, in November 2025, Lumenis Be. Ltd., an Israel-based energy-based medical device company, launched the Stellar M22 platform with XPL technology. This multi-application aesthetic system is designed to treat over 30 skin conditions, including rosacea. Stellar M22 combines four advanced technologies, features the new XPL Glide Mode for faster, in-motion treatments, and includes more than 850 built-in protocols to ensure repeatable and consistent results across diverse patient populations. Its hybrid modalities, such as PhotoFABULOUS and SmoothGlo, enable tailored skin rejuvenation regimens targeting vascular and pigment lesions common in rosacea, delivering rapid lesion clearance and improved comfort compared with conventional devices.

In September 2023, Mayne Pharma, an Australia-based specialty pharmaceutical company, acquired the global rights to RHOFADE (oxymetazoline hydrochloride) cream 1% from Novan, Inc. and EPI Health LLC for an undisclosed sum. This acquisition strengthened Mayne Pharma’s dermatology and rosacea portfolio by adding a proven topical therapy for persistent facial erythema associated with rosacea. Novan, Inc. is a US-based specialty dermatology company, and EPI Health LLC is a US-based specialty dermatology company focused on treatments for rosacea and acne.

Major companies operating in the rosacea market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., GlaxoSmithKline plc, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Galderma S.A., Dr. Reddy's Laboratories Ltd., Lupin Limited, LEO Pharma A/S, Almirall S.A., Taro Pharmaceuticals, Mayne Pharma, Aclaris Therapeutics Inc., Sol-Gel Technologies Ltd., Nestle Skin Health S.A., Foamix Pharmaceuticals.

North America was the largest region in the rosacea market in 2025. Asia-Pacific is expected to the fastest-growing region in the forecast period. The regions covered in the rosacea market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rosacea market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the rosacea market by increasing costs of imported active pharmaceutical ingredients, dermatology-grade excipients, and specialized packaging materials used in topical and oral formulations. Pharmaceutical manufacturers in North America and Europe are most affected due to dependence on imported APIs, while Asia-Pacific faces pricing pressure on formulation exports. These tariffs are raising production costs and influencing drug pricing strategies. However, they are also encouraging regional API manufacturing, localized drug formulation, and greater investment in domestic dermatology drug production capabilities.

The rosacea market research report is one of a series of new reports that provides rosacea market statistics, including rosacea industry global market size, regional shares, competitors with a rosacea market share, detailed rosacea market segments, market trends and opportunities, and any further data you may need to thrive in the rosacea industry. This rosacea market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Rosacea is a chronic skin condition that mainly affects the face, causing redness, flushing, and bumps, most commonly on the cheeks and nose. It usually develops in adulthood and is more prevalent among fair-skinned individuals. Symptoms of rosacea include swollen red bumps, visible blood vessels, and pus-filled pimples.

The main types of rosacea include erythematotelangiectatic rosacea, papulopustular rosacea, ocular rosacea, and phymatous rosacea. Erythematotelangiectatic rosacea is a chronic inflammatory skin disorder that primarily affects the face, and its treatment generally involves a combination of topical medications. The therapeutic options include various drug classes such as antibiotics, alpha-agonists, retinoids, corticosteroids, immunosuppressants, and others, which can be administered orally or topically. These treatments are used by multiple end users, including hospitals, clinics, retail pharmacies, and online pharmacies.

The rosacea market consists of sales of metronidazole, azelaic acid, brimonidine, oxymetazoline and tretinoin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.